KIT and intrahepatic cholangiocarcinoma: Accumulating studies have confirmed that TMEM16A is exclusively expressed in ICC of the muscular layer of the GI tract [29] and is a highly specific biomarker of ICC, exhibiting more selective labeling of ICC than Kit antibodies [20].